Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?
Roberto Latagliata(Ospedale di Belcolle), Robin Foà(Sapienza University of Rome), Matteo Molica(Sapienza University of Rome), Daniela Diverio(Policlinico Umberto I), Laura Cesini(Policlinico Umberto I), Gioia Colafigli(Policlinico Umberto I), Fulvio Massaro(Policlinico Umberto I), Federico Vozella(Campus Bio Medico University Hospital), Ida Carmosino(Policlinico Umberto I), Martina Canichella(ASL Roma), Luisa Quattrocchi(Policlinico Umberto I), Maria Giovanna Loglisci(Policlinico Umberto I), Marco Mancini(Radboud University Nijmegen), Maria Lucia De Luca(Sapienza University of Rome), Massimo Breccia(Policlinico Umberto I), Daniela De Benedittis(Sapienza University of Rome), Sara Mohamed(Royal College of Surgeons in Ireland - Bahrain), Melissa Campanelli(Policlinico Umberto I), Giuliana Alimena
Cited by 6
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity
|Cytokine|2015|505
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464